• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.南印度泰米尔人中阿托伐他汀引起的药物不良反应
J Clin Diagn Res. 2017 Jul;11(7):FC01-FC05. doi: 10.7860/JCDR/2017/27223.10175. Epub 2017 Jul 1.
2
Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series.他汀类药物治疗期间的情绪、人格和行为变化:病例系列
Drug Saf Case Rep. 2016 Dec;3(1):1. doi: 10.1007/s40800-015-0024-2.
3
Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs in a Tertiary Care Teaching Hospital.三级护理教学医院中报告的心血管药物不良反应模式
J Clin Diagn Res. 2015 Nov;9(11):FC01-4. doi: 10.7860/JCDR/2015/13810.6704. Epub 2015 Nov 1.
4
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.在 Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm(ASCOT-LLA)中,与未设盲、但与设盲他汀类药物治疗相关的不良事件:一项随机、双盲、安慰剂对照试验及其非随机、非盲扩展阶段。
Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2.
5
Physicians' Experiences as Patients with Statin Side Effects: A Case Series.医生作为他汀类药物副作用患者的经历:病例系列
Drug Saf Case Rep. 2017 Dec;4(1):3. doi: 10.1007/s40800-017-0045-0.
6
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.富含甘油三酯的脂蛋白胆固醇与 TNT 试验中接受他汀类药物治疗的患者心血管事件风险的关系。
Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.
7
Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients.一项随机对照试验,比较初治血脂异常患者每日及隔日服用阿托伐他汀治疗的疗效及其与血清羟甲基戊二酰辅酶A还原酶水平的相关性。
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S64-S67. doi: 10.1016/j.ihj.2018.05.010. Epub 2018 May 26.
8
Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis.SLCO1B1 多态性与阿托伐他汀安全性和疗效的关联:一项荟萃分析。
Curr Pharm Des. 2018;24(34):4044-4050. doi: 10.2174/1381612825666181219163534.
9
Adverse Drug Reactions Attributed to Fondaparinux and Unfractionated Heparin in Cardiovascular Care Unit: An Observational Prospective Pilot Study in a Tertiary Care Hospital.心血管监护病房中与磺达肝癸钠和普通肝素相关的药物不良反应:一家三级护理医院的前瞻性观察性试点研究。
J Pharm Bioallied Sci. 2018 Apr-Jun;10(2):90-95. doi: 10.4103/JPBS.JPBS_17_18.
10
DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).印度高危血脂异常患者血脂控制程度的人口统计学评估与评价(DIVERSE研究)
J Assoc Physicians India. 2016 Apr;64(4):38-46.

引用本文的文献

1
Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections.阿托伐他汀与伏立康唑(用于治疗血脂异常和真菌感染的药物)之间的相互作用及潜在机制。
Front Pharmacol. 2023 May 11;14:1165950. doi: 10.3389/fphar.2023.1165950. eCollection 2023.
2
Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis.阿托伐他汀与肝毒性风险的关联:一项初步的处方序列对称性分析。
Ther Clin Risk Manag. 2019 Jun 27;15:803-810. doi: 10.2147/TCRM.S204860. eCollection 2019.
3
[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study].[阿托伐他汀与伏立康唑在大鼠血浆中的相互作用:基于高效液相色谱-串联质谱法的研究]
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Mar 30;39(3):337-343. doi: 10.12122/j.issn.1673-4254.2019.03.12.

本文引用的文献

1
Cellular and molecular mechanisms of statins: an update on pleiotropic effects.他汀类药物的细胞和分子机制:多效性作用的最新进展
Clin Sci (Lond). 2015 Jul;129(2):93-105. doi: 10.1042/CS20150027.
2
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.糖尿病前期和非糖尿病前期人群接受大剂量他汀类药物治疗后新发糖尿病的风险及心血管风险降低情况:来自TNT和IDEAL研究的分析
J Am Coll Cardiol. 2015 Feb 3;65(4):402-404. doi: 10.1016/j.jacc.2014.10.053.
3
Statin adverse effects: sorting out the evidence.他汀类药物的不良反应:梳理证据
J Fam Pract. 2014 Sep;63(9):497-506.
4
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.巴西南部队列中辛伐他汀/阿托伐他汀治疗疗效和安全性的性别差异评估。
Arq Bras Cardiol. 2014 Jul;103(1):33-40. doi: 10.5935/abc.20140085.
5
A current approach to statin intolerance.一种目前的他汀不耐受处理方法。
Clin Pharmacol Ther. 2014 Jul;96(1):74-80. doi: 10.1038/clpt.2014.84. Epub 2014 Apr 11.
6
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).体重变化对阿托伐他汀治疗稳定型冠状动脉疾病患者新发糖尿病的影响(来自治疗至新目标研究)。
Am J Cardiol. 2014 May 15;113(10):1593-8. doi: 10.1016/j.amjcard.2014.02.011. Epub 2014 Mar 1.
7
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.药物代谢酶和药物转运体编码基因的遗传多态性分布——印度视角的综述
Indian J Med Res. 2014 Jan;139(1):27-65.
8
Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).阿托伐他汀80毫克与40毫克用于印度急性冠状动脉综合征患者的临床经验的上市后研究——一项随机、多中心研究(CURE-ACS)。
J Assoc Physicians India. 2013 Feb;61(2):97-101.
9
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南:美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
10
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.在3227例患者的短期观察中,阿托伐他汀40mg在日常临床实践中的安全性和耐受性。
Przegl Lek. 2013;70(6):373-6.

南印度泰米尔人中阿托伐他汀引起的药物不良反应

Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.

作者信息

Indumathi Chandrasekaran, Anusha Natarajan, Vinod Kolar Vishwanath, Santhosh Satheesh, Dkhar Steven Aibor

机构信息

PhD Scholar, Department of Pharmacology, JIPMER, Puducherry, India.

Senior Resident, Department of Pharmacology, JIPMER, Puducherry, India.

出版信息

J Clin Diagn Res. 2017 Jul;11(7):FC01-FC05. doi: 10.7860/JCDR/2017/27223.10175. Epub 2017 Jul 1.

DOI:10.7860/JCDR/2017/27223.10175
PMID:28892923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5583921/
Abstract

INTRODUCTION

Atorvastatin is the most widely used statin world-over. Although atorvastatin is beneficial in reducing cardiovascular morbidity and mortality, they are associated with Adverse Drug Reactions (ADRs) which are under-recognized as well as under-reported. There is no data on safety of atorvastatin in ethnic populations like South Indian Tamils and hence the need for this study.

AIM

To report the Adverse Events (AEs) associated with atorvastatin use, their causality and severity in dyslipidemic south Indian Tamils.

MATERIALS AND METHODS

This cross-sectional study was carried out on 304 dyslipidemic Tamils. Those on any lipid lowering therapy within one month before study enrolment, those with contraindications to statin therapy, hypothyroid patients, those with LDL cholesterol >250 mg/dL or serum triglycerides >400 mg/dL and patients who were on drugs which modulate Cytochrome P 450 3A4/5 (CYP3A4/5) activity were excluded from the study. Causality assessment for atorvastatin induced AEs were done using Naranjo adverse drug reaction probability scale criteria and severity assessment was done using Hartwig scale. AEs which were causally related to atorvastatin use were reported as ADRs.

RESULTS

One hundred and eighty three AEs were noted among 145 (47.7%) patients, during the course of first 45 days of atorvastatin therapy. AEs were probably due to atorvastatin in 11% of the patients and possibly due to atorvastatin in 89%. Most common ADRs were myalgia (41%), followed by nervous system ADRs (35.5%) and gastrointestinal ADRs (14%).

CONCLUSION

Myalgia was the most common cause for atorvastatin discontinuation which might place these individuals at an increased risk of cardiovascular morbidity and mortality. Measures to identify and address atorvastatin induced myalgia should be given priority.

摘要

引言

阿托伐他汀是全球使用最广泛的他汀类药物。尽管阿托伐他汀在降低心血管发病率和死亡率方面有益,但它们与药物不良反应(ADR)相关,这些不良反应未得到充分认识和报告。在南印度泰米尔人等种族人群中,没有关于阿托伐他汀安全性的数据,因此需要进行这项研究。

目的

报告血脂异常的南印度泰米尔人使用阿托伐他汀相关的不良事件(AE)、其因果关系和严重程度。

材料与方法

对304名血脂异常的泰米尔人进行了这项横断面研究。在研究入组前一个月内接受任何降脂治疗的患者、他汀类药物治疗有禁忌症的患者、甲状腺功能减退患者、低密度脂蛋白胆固醇>250mg/dL或血清甘油三酯>400mg/dL的患者以及正在服用调节细胞色素P450 3A4/5(CYP3A4/5)活性药物的患者被排除在研究之外。使用Naranjo药物不良反应概率量表标准对阿托伐他汀引起的AE进行因果关系评估,并使用Hartwig量表进行严重程度评估。与阿托伐他汀使用有因果关系的AE被报告为ADR。

结果

在阿托伐他汀治疗的前45天内,145名(47.7%)患者中记录到183例AE。11%的患者AE可能归因于阿托伐他汀,89%的患者可能归因于阿托伐他汀。最常见的ADR是肌痛(41%),其次是神经系统ADR(35.5%)和胃肠道ADR(14%)。

结论

肌痛是阿托伐他汀停药的最常见原因,这可能使这些个体心血管发病和死亡风险增加。应优先采取措施识别和处理阿托伐他汀引起的肌痛。